Please login to the form below

Not currently logged in
Email:
Password:

stem cells

This page shows the latest stem cells news and features for those working in and with pharma, biotech and healthcare.

Bluebird Bio reveals further encouraging data for CALD gene therapy

Bluebird Bio reveals further encouraging data for CALD gene therapy

Other potential complications include graft-versus-host (GvHD) disease, when the transplanted cells recognise the recipient’s cells as foreign and attack them. ... Bluebird's treatment works by extracting patients' stem cells and modifying them with

Latest news

  • Vertex eyes type 1 diabetes cure with biotech acquisition Vertex eyes type 1 diabetes cure with biotech acquisition

    According to Vertex, the biotech is pioneering the use of stem cells as a potential cure for type 1 diabetes. ... The biotech has advanced the ability to produce large quantities of functional human pancreatic beta cells that restore insulin production

  • Bayer takes control of BlueRock stem cell joint venture Bayer takes control of BlueRock stem cell joint venture

    Bayer has held a 41% stake in the company since then, and taking overall control suggests it is impressed with the platform BlueRock has built in induced pluripotent stem cells (iPSCs). ... BlueRock is also developing iPSCs that differentiate into

  • Mereo’s shareholders back OncoMed takeover

    California-based OncoMed was formed in 2004 to develop antibody drugs targeting cancer stem cells – known as tumour-initiating cells – and managed to gather a sizeable group of development partners including

  • Promethera’s liver failure stem cell therapy clears first hurdle Promethera’s liver failure stem cell therapy clears first hurdle

    It consists of liver stem cells harvested from donated healthy organs, which are intended to migrate from the blood to the liver, implanting and helping the diseased tissue regenerate. ... In the trial, HepaStem liver stem cells were infused

  • Bluebird gets European recommendation for gene therapy Zynteglo Bluebird gets European recommendation for gene therapy Zynteglo

    a patient’s own haematopoietic (blood) stem cells (HSCs). ... This includes the first specialist therapy sites set up to perform the collection and removal of the patient’s own haematopoietic (blood) stem cells (HSCs), called apheresis.

More from news
Approximately 5 fully matching, plus 101 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    CTX001 is an ex vivo therapy, meaning. the CRISPR technology is used to modify haematopoietic stem cells outside the body to express foetal haemoglobin, and then reinfused into the patient. ... hope was that - without the brake of PD-1 – the edited

  • 30 Women Leaders in UK Healthcare (part 3) 30 Women Leaders in UK Healthcare (part 3)

    Kathy Niakan is a group leader at London's academic research hub The Francis Crick Institute.and is investigating the mechanisms of lineage specification in human embryos and stem cells. ... of infertility, miscarriages and developmental disorders, and

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead asset, allogeneic expanded adipose-derived stem cells (eASC) locally administered for

  • Deal Watch December 2016 Deal Watch December 2016

    320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for neurodegenerative diseases. ... the affinity and selectivity of antibodies with the properties of small molecules, Evotec's induced pluripotent stem cells

  • Deal Watch July 2016 Deal Watch July 2016

    It is a humanised inducible co-stimulator (ICOS) agonist antibody, designed to both stimulate T effector cells and selectively reduce intra-tumoural T regulatory cells. ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment for perianal

More from intelligence
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics